BACKGROUND AND AIMS: Molecular target therapy against L-type amino acid transporter 1 (LAT1) is unique and expected to be developed soon. LAT1 expression was investigated in pancreatic cancer as a prognostic predictor. METHODS: Surgically resected pancreatic ductal adenocarcinomas (PDAC, n=66) were investigated using immunohistochemistry. For reference, intraductal papillary mucinous carcinomas (IPMC, including intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia or with an associated invasive carcinoma, n=13) and adenomas (IPMA, including IPMN with low- and intermediate-grade dysplasia, n=5) were also examined. RESULTS: LAT1 expression scores increased from PDAC to IPMA to IPMC. Kaplan-Meier analysis showed significant differences between LAT1-high and -low scores in PDAC. Even in each Ki-67-labelling index (LI) low and high PDAC group (cut off 40%), high LAT1 expression could also predict poor prognosis. Multivariable analysis showed that LAT1 expression, Ki-67 LI, tumour differentiation and size were individual prognostic factors. CONCLUSIONS: LAT1 aberrant overexpression in PDAC predicts poor prognosis, independent of Ki-67 LI, and offers a potential target for future anticancer therapy with its inhibitors.
BACKGROUND AND AIMS: Molecular target therapy against L-type amino acid transporter 1 (LAT1) is unique and expected to be developed soon. LAT1 expression was investigated in pancreatic cancer as a prognostic predictor. METHODS: Surgically resected pancreatic ductal adenocarcinomas (PDAC, n=66) were investigated using immunohistochemistry. For reference, intraductal papillary mucinous carcinomas (IPMC, including intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia or with an associated invasive carcinoma, n=13) and adenomas (IPMA, including IPMN with low- and intermediate-grade dysplasia, n=5) were also examined. RESULTS:LAT1 expression scores increased from PDAC to IPMA to IPMC. Kaplan-Meier analysis showed significant differences between LAT1-high and -low scores in PDAC. Even in each Ki-67-labelling index (LI) low and high PDAC group (cut off 40%), high LAT1 expression could also predict poor prognosis. Multivariable analysis showed that LAT1 expression, Ki-67 LI, tumour differentiation and size were individual prognostic factors. CONCLUSIONS:LAT1 aberrant overexpression in PDAC predicts poor prognosis, independent of Ki-67 LI, and offers a potential target for future anticancer therapy with its inhibitors.
Authors: Stephen G Dann; Michael Ryskin; Anthony M Barsotti; Jonathon Golas; Celine Shi; Miriam Miranda; Christine Hosselet; Luanna Lemon; Judy Lucas; Maha Karnoub; Fang Wang; Jeremy S Myers; Scott J Garza; Maximillian T Follettie; Kenneth G Geles; Anke Klippel; Robert A Rollins; Valeria R Fantin Journal: EMBO J Date: 2015-05-15 Impact factor: 11.598
Authors: Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal Journal: HPB (Oxford) Date: 2016-07-14 Impact factor: 3.647
Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: C Rosilio; M Nebout; V Imbert; E Griessinger; Z Neffati; J Benadiba; T Hagenbeek; H Spits; J Reverso; D Ambrosetti; J-F Michiels; B Bailly-Maitre; H Endou; M F Wempe; J-F Peyron Journal: Leukemia Date: 2014-12-08 Impact factor: 11.528